In addition, targeting the ubiquitin-proteasome system (UPS), with Bortezomib, combined with HDAC6 inhibition was shown to (i) successfully kill ovarian cancer cells in vitro and (ii) reduce ovarian cancer cell spreading and migration as a result of the deacetylation of α-tubulin by HDAC6 [22]. This evidence concerns the gene HDAC6 and ovarian cancer.